Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon
Hepatitis Research and Treatment · 2010
DOI: 10.1155/2010/537827 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatitis Research and Treatment, 2010. Verfasst von Douglas F Meyer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Digestive Diseases, Beth Israel Medical Center and Albert Einstein, College of Medicine, New York, NY 10003, USA. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Background
Current treatment of chronic hepatitis C with pegylated interferon and ribavirin has the ability to eliminate viral infection in about half of the patients treated. Therapeutic options, for those with remaining chronic hepatitis, will remain limited until novel antivirals become available in the future. Consensus interferon is currently available and has demonstrated clinical efficacy with superior invitro antiviral activity, but the maximum tolerated dose is not defined.
Methods
We assessed the efficacy of daily high-dose (24 ug) consensus interferon with weight-based (1000–1200 mg daily) ribavirin in HCV genotype 1-infected non-responder patients.
Results
Six adverse events were documented in five patients, and the trial was terminated with no subject achieving viral clearance.
Conclusions
The occurrence of serious adverse events effectively defined the upper limit of acceptable dose, while also revealing that this dose did not offer enhanced sustained viral clearance.
Autor:innen und Institutionen
- Division of Digestive Diseases, Beth Israel Medical Center and Albert Einstein, College of Medicine, New York, NY 10003, USA.
Zitieren
APA
Meyer, D. F., Tobias, H., Min, A. D., Rajendra, A., Zic, I., Brettholz, E., Clain, D. J., Klion, F., Bernstein, D., & Bodenheimer, H. C. (2010). Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon. Hepatitis Research and Treatment. https://doi.org/10.1155/2010/537827
Vancouver
Meyer DF, Tobias H, Min AD, Rajendra A, Zic I, Brettholz E, et al. Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon. Hepatitis Research and Treatment. 2010. doi:10.1155/2010/537827
BibTeX
@article{Meyer2010,
author = {Meyer, Douglas F and Tobias, Hillel and Min, Albert D and Rajendra, Arathi and Zic, Ivanka and Brettholz, Edward and Clain, David J and Klion, Franklin and Bernstein, David and Bodenheimer, Henry C},
title = {Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon},
journal = {Hepatitis Research and Treatment},
year = {2010},
doi = {10.1155/2010/537827}
}
EUVIMED